Efficacy of AposTherapy® in Knee OA
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03153956 |
Recruitment Status :
Terminated
(Halt in funding)
First Posted : May 15, 2017
Results First Posted : March 24, 2020
Last Update Posted : March 24, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis, Knee | Device: Calibrated AposTherapy® Device: Non-Calibrated Sham Apos Therapy Device | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 77 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Phase I - A prospective, interventional, randomized, double-arm clinical evaluation of patients who have been diagnosed with OA of the knee. The active treatment arm (personally calibrated biomechanical device) will be compared to a control arm (sham-placebo device) (similar shoes without biomechanical elements). Phase II - Open-label, cross-over study design. After the completion of phase one patients will be un-blinded to their group allocation. Patients that were allocated to the sham-placebo control group will cross to the active group and will receive the AposTherapy treatment. Patients that were allocated to the active group will continue with treatment. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective, Randomized Double-Armed Efficacy Evaluation of AposTherapy® for the Treatment of Knee Osteoarthritis |
Actual Study Start Date : | April 16, 2015 |
Actual Primary Completion Date : | November 15, 2018 |
Actual Study Completion Date : | November 15, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Active Treatment Arm
Personally calibrated bio-mechanical device
|
Device: Calibrated AposTherapy®
a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. |
Placebo Comparator: Control Arm
sham-placebo device (similar shoes without bio-mechanical elements).
|
Device: Non-Calibrated Sham Apos Therapy Device
The comparator group will receive a non-calibrated sham device. |
- Western Ontario and McMaster University (WOMAC) Total Score [ Time Frame: screening, 3 months, 6 months, 9 months, and 12 months ]WOMAC evaluates the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. In this study, WOMAC scores were recomputed as the sum within sub-scales (pain score is the sum of questions 1-5; stiffness is the sum of questions 6-7; functional score is the sum of questions 8-24). The total score is reported as the sum of the pain, stiffness, and functional sub-scores for all participants. The total score range is 0-1292. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
- Visual Analog Score (VAS) Score [ Time Frame: 12 Months ]The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.
- Short-Form 36 (SF-36) Total Score [ Time Frame: screening, 3 months, 6 months, 9 months, and 12 months ]The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The survey consists eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0-100, with lower scores = more disability and higher scores = less disability. Therefore, higher scores represent better health.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients suffering from symptomatic unilateral or bilateral knee OA at the medial compartment for at least six months;
- Fulfilling the ACR clinical criteria;
- Having radiographically assessed OA of the knee with a Kellgren-Lawrence grade more than or equal to grade 2; and,
- Having VAS-Pain ≥ 3, on a scale between 0-10.
- Patients who have a shoe size between US 4 and US 12
Exclusion Criteria:
- Patients suffering from acute septic arthritis.
- Patients who received a corticosteroid injection within 3 months of the study.
- Patients who received hyaluronic acid (HA) injections within 6 months of the study
- Patients suffering from avascular necrosis of the knee.
- Patients with a history of knee buckling or recent knee injury.
- Patients who have had a joint replacement or other major surgery to the knee, hip or ankle (ipsilateral or contralateral side).
- Patients suffering from neuropathic arthropathy.
- Patients with an increased tendency to fall.
- Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure.
- Patients with a history of pathological osteoporotic fracture.
- Patients suffering from symptomatic degenerative arthritis in lower limb joints other than the knees.
- Patients with referred pain in the knees from primary back or hip joint pain.
- Patients with neurological deficits to the lower extremity (ex. foot drop)
- Patients whose shoe size is less than US 4 and greater than US 12
- Patients who have had arthroscopy within 6 months of the study
- Patients with inflammatory arthropathy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03153956
United States, New York | |
New York University School of Medicine | |
New York, New York, United States, 10016 |
Principal Investigator: | Dennis Cardone, DO | NYU Langone Health |
Documents provided by NYU Langone Health:
Responsible Party: | NYU Langone Health |
ClinicalTrials.gov Identifier: | NCT03153956 |
Other Study ID Numbers: |
14-02127 |
First Posted: | May 15, 2017 Key Record Dates |
Results First Posted: | March 24, 2020 |
Last Update Posted: | March 24, 2020 |
Last Verified: | March 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
AposTherapy® System Osteoarthritis Total knee arthroplasties Degenerative joint disease |
Osteoarthritis Osteoarthritis, Knee Arthritis |
Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |